Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome

Next Previous
Search
Trial Profile

Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Adverse reactions
  • Acronyms SETS aHUS

    • Most Recent Events

    • 02 Dec 2023 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2021 Status changed from recruiting to active, no longer recruiting.
    • 03 Sep 2021 Planned End Date changed from 31 Aug 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top